APO-CILAZAPRIL/HCTZ 12.5 MG
HYDROCHLOROTHIAZIDE : 12.5 MG CILAZAPRIL (CILAZAPRIL MONOHYDRATE) : 5 MG · DIN 02284987 · APOTEX INC
Health Canada status: MARKETED
What is APO-CILAZAPRIL/HCTZ?
APO-CILAZAPRIL/HCTZ 12.5 MG contains HYDROCHLOROTHIAZIDE : 12.5 MG CILAZAPRIL (CILAZAPRIL MONOHYDRATE) : 5 MG. It is listed in the Health Canada Drug Product Database under DIN 02284987, held by APOTEX INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 23-Aug-2006. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is APO-CILAZAPRIL/HCTZ used for?
Treatment of mild to moderate essential hypertension in patients for whom combination therapy is appropriate. Not indicated for initial therapy.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02284987 |
|---|---|
| Brand name | APO-CILAZAPRIL/HCTZ |
| Generic / active ingredient | HYDROCHLOROTHIAZIDE : 12.5 MG CILAZAPRIL (CILAZAPRIL MONOHYDRATE) : 5 MG |
| Manufacturer | APOTEX INC |
| Strength | 12.5 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | C09BA08 CILAZAPRIL AND DIURETICS |
| AHFS class | 40:28.20 ; 24:32.04 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 23-Aug-2006 |
| Original market date | 2006-08-23 00:00:00 |
How is it administered?
Individualized by titration. Not for initial therapy. Usually taken once daily with water, with or without food. Avoid in severe renal impairment (CrCl < 10 mL/min).
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly detailed in provided text (standard section 11 reference), but usually 15-30°C for such products.
How is it supplied?
Bottles of 100 tablets.
Contraindications
Hypersensitivity to components or sulfonamides; history of ACEI-related angioedema; ascites; anuria; pregnancy; breast-feeding; concomitant aliskiren in diabetes/renal impairment; neprilysin inhibitors.
Warnings and precautions
Fetal toxicity; angioedema (risk higher in Black patients); hypotension; dual blockade of RAS; non-melanoma skin cancer risk; neutropenia/agranulocytosis; photosensitivity.
What can be used instead?
Other Canadian products sharing ATC code C09BA08 CILAZAPRIL AND DIURETICS. 2 of 3 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| INHIBACE PLUS | 12.5 MG | TABLET | CHEPLAPHARM ARZNEIMITTEL GMBH | MARKETED | DIN 02181479 |
| TEVA-CILAZAPRIL/HCTZ | 5 MG | TABLET | TEVA CANADA LIMITED | CANCELLED POST MARKET | DIN 02313731 |
Who else supplies CILAZAPRIL AND DIURETICS worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. CILAZAPRIL AND DIURETICS appears in 16 registered pack listings across 7 markets, published on 5 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.